[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571434":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":10,"responsibleParty":18,"collaborators":10,"id":20,"slug":21,"hasResults":22,"nctId":23,"briefTitle":24,"officialTitle":25,"acronym":10,"eligibilityCriteria":26,"healthyVolunteers":22,"sex":27,"minAge":28,"maxAge":10,"enrollmentInfo":29,"targetDuration":32,"studyType":33,"phases":10,"briefSummary":34,"conditions":35,"keywords":38,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":10},{"fullName":5,"class":6},"Shanghai East Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Research group",null,"It is expected to include 30 newly diagnosed NHL or MM patients, and the tracer radiation used in the study is extremely small and will not have any physiological effects on the subjects.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Jie Ding, MD","CONTACT","086-38804518","dingjie940406@163.com",{"type":19,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100571434","efficacy-of-68ga-pentixafor-petmr-in-detecting-non-hodgkin-lymphoma-and-multiple-myeloma-lesions-100571434",false,"NCT06720207","Efficacy of 68Ga-Pentixafor PET\u002FMR in Detecting Non-Hodgkin Lymphoma and Multiple Myeloma Lesions","Exploratory Study on the Efficacy of 68Ga-Pentixafor PET\u002FMR in Detecting Lesions in Non-Hodgkin Lymphoma and Multiple Myeloma","Inclusion Criteria:\n\n1. Age of 18 years or older\n2. ECOG \\\u003C 2\n3. Newly diagnosed patients with NHL and MM who have been confirmed or are highly suspected based on pathological examination\n4. Completion of 18F-FDG PET\u002FCT or PET\u002FMR imaging within the past week in our department\n\nExclusion Criteria:\n\n1. Pregnant and breastfeeding women;\n2. Individuals with severe hepatic and renal failure;\n3. Patients with concurrent malignancies;\n4. Individuals unable to remain supine for a duration of 30 minutes to complete the examination;\n5. Patients with diagnosed claustrophobia;\n6. Patients containing metallic implants;\n7. Individuals deemed unsuitable for participation in clinical trials by researchers.","ALL","18 Years",{"count":30,"type":31},30,"ESTIMATED","3 Years","OBSERVATIONAL","In this study, the investigators intend to utilize 68Ga-Pentixafor Positron Emission Tomography（PET） imaging for patients diagnosed with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). The investigators will compare the imaging results with those obtained from 18F-FDG imaging, and a correlation analysis will be performed to assess progression-free survival among patients. This analysis aims to evaluate the diagnostic efficacy and the potential for early prediction of treatment efficacy associated with 68Ga-Pentixafor in these specific conditions.",[36,37],"Non Hodgkin's Lymphoma","Multiple Myeloma (MM)",[39,36,40],"PET\u002FMR","multiple myeloma","NOT_YET_RECRUITING","2025-06-24",{"date":44,"type":45},"2025-06-27","ACTUAL",{"date":47,"type":31},"2025-07-01",{"date":49,"type":31},"2027-07-31",{"name":5,"class":6}]